SLC5A2 and heart failure: More recently, the benefits of an SGLT2 inhibitor in treating established HF were demonstrated in the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening HF or Cardiovascular Death in Patients with Chronic HF) and the EMPEROR-Reduced (Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure) trial [7, 8].